Business Wire

CA-NETAPP

5.3.2024 14:01:30 CET | Business Wire | Press release

Share
NetApp Fights Ransomware in Real-Time with Built-In Artificial Intelligence on Enterprise Storage and Enhanced Cyber-Resiliency Solutions

NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced cyber-resiliency capabilities that will equip customers to better protect and recover their data in the face of ransomware threats. NetApp is one of the first to integrate artificial intelligence (AI) and machine learning (ML) directly into enterprise primary storage to fight ransomware in real-time. The NetApp cyber-resiliency capabilities protect both primary and secondary data for organizations whether it is stored on-premises or in the cloud.

Cybercriminals are increasingly aiming ransomware attacks at critical infrastructure and supply chains where operational disruptions can cost millions of dollars, according to Forrester. As a result, 87 percent of C-suite and board-level executives ranked ransomware as a high, or the top, priority for their organization, according to the NetApp 2023 Data Complexity report. When cybercriminals breach perimeters, networks, and identities storage becomes the last line of defense for organizations’ most critical data. With the threat of ransomware looming, organizations need solutions that not only protect their data but also quickly recover lost data and return to normal operations. NetApp is updating its cyber-resiliency solutions and leveraging the power of AI to give customers confidence that their data will be safe and accessible when they need it.

“NetApp is taking an aggressive and proactive approach to protecting our customers’ data against cyber threats using artificial intelligence. We are the first storage vendor to explicitly and financially guarantee our data storage offerings against ransomware,” said Mignona Cote, CSO at NetApp. “Today, we are furthering that leadership with updates that make defending data comprehensive, continuous, and simple for our customers.”

NetApp is focused on designing data storage and management systems that maximize data protection and security while meeting data governance and compliance standards, with new updates that include:

  • ONTAP Autonomous Ransomware Protection with Artificial Intelligence (ARP/AI) will spearhead the next generation of real-time enterprise storage ransomware protection, giving increased accuracy and performance required to detect and mitigate new, more sophisticated cyber threats. NetApp pioneered autonomous real-time detection of ransomware directly in primary enterprise storage three years ago. Now, NetApp will be leading the charge to use adaptive AI/ML models built directly into enterprise primary storage to look at file-level signals in real-time to detect even the newest ransomware attacks with planned 99%+ precision and recall. NetApp will be offering the first technology preview of ARP/AI within the next quarter.
  • NetApp BlueXP Ransomware Protection, now in public preview, provides a single control plane to intelligently coordinate and execute an end-to-end, workload-centric ransomware defense. Customers can now identify and protect critical workload data with a single click, accurately and automatically detect and respond to a potential attack, and recover workloads within minutes, safeguarding their valuable data and minimizing costly disruption.
  • Application-Aware Ransomware Protection via NetApp SnapCenter 5.0 offers immutable ransomware protection for applications. SnapCenter will now apply NetApp's leading ransomware protection technologies, previously used with unstructured data, to application-consistent backup. SnapCenter 5.0 includes support for key ONTAP features like tamperproof Snapshot copy locking, SnapLock protected volumes, and SnapMirror Business Continuity to enable more robust data protection for applications and virtual machines. SnapCenter 5.0 supports protection of applications on-premises with NetApp AFF, ASA, and FAS, as well as in the cloud.
  • NetApp BlueXP Disaster Recovery, now generally available, offers seamless integration with VMware infrastructure and provides storage options for both on-premises and major public cloud environments. This comprehensive solution eliminates the need for separate standby disaster recovery (DR) infrastructure, reducing costs. With NetApp BlueXP disaster recovery, failover and failback processes are simplified, allowing smooth transitions from on-premises VMware infrastructure to the public cloud or to an on-premises data center.
  • NetApp Keystone Ransomware Recovery Guarantee extends NetApp’s current Ransomware Recovery Guarantee to our leading storage-as-a-service offering, NetApp Keystone. With this guarantee, NetApp will warrant snapshot data recovery in the event of a ransomware attack. If snapshot data copies can’t be recovered through NetApp, we will offer compensation*.

“Today’s cybersecurity teams face the monumental task of protecting their companies’ data from ever-evolving threats, especially ransomware,” said Archana Venkatraman, Research Director, Cloud Data Management, IDC. “NetApp’s approach of delivering a secure, unified storage infrastructure makes storage foundational for ransomware protection and reduces the burden on cybersecurity teams. Companies looking to fortify their cyber resiliency and shifting protection left will increasingly look to vendors that take a secure-by-design approach and develop unified storage and data services.”

“Using NetApp in our Advanced Technology Center, we significantly simplified our replication process for VMware virtual machines and their underlying datastores to meet or exceed recovery benchmarks,” said Derek Elbert, Solutions Architect at WWT. “With NetApp’s solutions, we successfully established the recovery policies for cloud volumes workloads or virtual machines with no existing DR strategy, managing everything through NetApp BlueXP. This transforms how we operate disaster recovery for VMware.”

“To store sensitive genomics and health data, we have to use the right technology with layers of security built in,” said Mark Cowley, Deputy Director at Children’s Cancer Institute. “With NetApp, we can be very confident that we are sharing the right data only to authorized researchers. The last line of defense is your weakest web-based system, so we’ve implemented role-based access and added resilience to all of our tools.”

The latest cyber resiliency updates from NetApp empower organizations to proactively address cybersecurity threats in complex hybrid and multicloud environments, leveraging AI to identify threats and prevent disruptions to their operations.

To learn more about the NetApp cyber-resiliency offerings visit: https://www.netapp.com/cyber-resilience/

*Specific terms and conditions will apply. Customers must apply for coverage by the guarantee.

Additional Resources

About NetApp

NetApp is the intelligent data infrastructure company, combining unified data storage, integrated data services, and CloudOps solutions to turn a world of disruption into opportunity for every customer. NetApp creates silo-free infrastructure, harnessing observability and AI to enable the industry’s best data management. As the only enterprise-grade storage service natively embedded in the world’s biggest clouds, our data storage delivers seamless flexibility. In addition, our data services create a data advantage through superior cyber resilience, governance, and application agility. Our CloudOps solutions provide continuous optimization of performance and efficiency through observability and AI. No matter the data type, workload, or environment, with NetApp you can transform your data infrastructure to realize your business possibilities. Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.

NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240305981204/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye